{"id":"W2019837162","doi":"10.1007/s10637-014-0169-3","title":"A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Bevacizumab; Mucositis; Discontinuation; Internal medicine; Interim analysis; Gastroenterology; Sorafenib; Hepatocellular carcinoma; Phases of clinical research; Clinical endpoint; Progression-free survival; Surgery; Toxicity; Clinical trial; Chemotherapy; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000186887,0.0002524869,0.0005041728,0.0002326816,0.00007238749,0.000009698931,0.0001050844,0.0001107273,0.00006317124],"category_scores_gemma":[0.0001284107,0.0002098867,0.000114985,0.0003776997,0.0001430017,0.0001416167,0.00003972639,0.0001626936,0.00001572221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001482907,"about_ca_system_score_gemma":0.0007056521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002091804,"about_ca_topic_score_gemma":0.000008596011,"domain_scores_codex":[0.9980944,0.00008416642,0.0005161559,0.0003656822,0.0006628954,0.0002766313],"domain_scores_gemma":[0.9988712,0.0001003379,0.0002060475,0.0003214132,0.000162503,0.0003385149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03379832,0.002317403,0.950132,0.00008618218,0.00008314189,0.00002453148,0.001167352,0.00001772246,0.0006441148,0.0009113421,0.00022805,0.0105899],"study_design_scores_gemma":[0.8174748,0.02629863,0.1203263,0.0003900008,0.0003613514,0.000009375,0.00005613058,0.01318205,0.01542744,0.00225471,0.003625797,0.0005934217],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966944,0.0000913575,0.00004842033,0.0007386092,0.00009359902,0.001494722,0.00002171265,0.00003696164,0.0007802008],"genre_scores_gemma":[0.9962184,0.000002305428,0.002438948,0.0002410422,0.0001679355,0.00008736914,0.0005033292,0.00003529199,0.000305395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8298057,"threshold_uncertainty_score":0.8558933,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0276207536430723,"score_gpt":0.2415496491141181,"score_spread":0.2139288954710458,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}